Skip to main content

Rite Aid Statement on CDC Recommendation Regarding COVID-19 Vaccine for Children Ages 5-11

On November 2, 2021, the Centers for Disease Control and Prevention (CDC) concurred with previous recommendations made by the Food and Drug Administration (FDA) and the Advisory Committee on Immunization Practices (ACIP), officially authorizing the emergency use of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include children 5 through 11 years of age.

The Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age is administered as a two-dose primary series, 3 weeks apart, but is a lower dose (10 micrograms) than that used for individuals 12 years of age and older (30 micrograms).

As a proud partner in the Federal Retail Pharmacy Program, Rite Aid is prepared to begin administering doses to children aged 5-11 as soon as the 10 microgram doses are distributed to Rite Aid, which is expected at the end of this week. The first available appointments for age 5-11 doses will be on Saturday, November 6. Those appointments may be booked through our scheduling tool beginning Thursday, November 4.

Due to the current supply of 10 microgram doses, only select Rite Aid locations will be offering appointments. Please visit our scheduling tool at www.riteaid.com to find a location near you, or check vaccines.gov for a complete list of national availability.

About Rite Aid Corporation

As the trusted, everyday care connector, Rite Aid drives lower health care costs through better coordination, stronger engagement, and personalized services that help you achieve whole health for life. We provide an array of whole being health products and services for the entire family through over 2,500 retail pharmacy locations across 17 states. Through Elixir, we provide pharmacy benefits and services to millions of members nationwide. For more information, www.riteaid.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.